|Bid||610.00 x N/A|
|Ask||739.90 x N/A|
|Day's Range||670.00 - 670.00|
|52 Week Range||599.58 - 1,500.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LA JOLLA, Calif., September 27, 2021--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the sponsorship of the San Diego Open, an ATP 250 tournament, and a partnership with San Diego native and tennis pro Brandon Nakashima. The sponsorships further represent DermTech’s commitment to the San Diego community and goal of raising awareness on the importance of sun safety and skin checks to
It will probably take IIP longer to double again, but achieving the goal within the next three to five years seems quite attainable. IIP is a real estate investment trust (REIT) that's focused on the medical cannabis market. The company has generated its growth so far by buying properties from medical cannabis operators, then leasing those properties back to the operators.
The iShares Biotechnology ETF (NASDAQ: IBB) has delivered a solid double-digit percentage gain. Meanwhile, the SPDR S&P Biotech ETF (NYSEMKT: XBI) is in negative territory year to date and is close to 25% below its February highs. The key to success for the iShares Biotechnology ETF (IBB) has been Moderna (NASDAQ: MRNA).